Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Gloeobacter violaceus Photosystem I iron-sulfur center (psaC) CSB-YP759493GCI
CSB-EP759493GCI
CSB-BP759493GCI
CSB-MP759493GCI
CSB-EP759493GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus UPF0367 protein gsr3177 (gsr3177) CSB-YP759494GCI
CSB-EP759494GCI
CSB-BP759494GCI
CSB-MP759494GCI
CSB-EP759494GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Polyribonucleotide nucleotidyltransferase (pnp), partial CSB-YP759495GCI
CSB-EP759495GCI
CSB-BP759495GCI
CSB-MP759495GCI
CSB-EP759495GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Anthranilate phosphoribosyltransferase (trpD) CSB-YP759496GCI
CSB-EP759496GCI
CSB-BP759496GCI
CSB-MP759496GCI
CSB-EP759496GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Photosystem I reaction center subunit III (psaF), partial CSB-YP759497GCI1
CSB-EP759497GCI1
CSB-BP759497GCI1
CSB-MP759497GCI1
CSB-EP759497GCI1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus 30S ribosomal protein S16 (rpsP) CSB-YP759498GCI
CSB-EP759498GCI
CSB-BP759498GCI
CSB-MP759498GCI
CSB-EP759498GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus ATP synthase subunit beta (atpD) CSB-YP759499GCI
CSB-EP759499GCI
CSB-BP759499GCI
CSB-MP759499GCI
CSB-EP759499GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Proline--tRNA ligase (proS), partial CSB-YP759500GCI
CSB-EP759500GCI
CSB-BP759500GCI
CSB-MP759500GCI
CSB-EP759500GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus tRNA modification GTPase MnmE (mnmE) CSB-YP759501GCI
CSB-EP759501GCI
CSB-BP759501GCI
CSB-MP759501GCI
CSB-EP759501GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Pyrrolidone-carboxylate peptidase (pcp) CSB-YP759502GCI
CSB-EP759502GCI
CSB-BP759502GCI
CSB-MP759502GCI
CSB-EP759502GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Light-independent protochlorophyllide reductase iron-sulfur ATP-binding protein (chlL) CSB-YP759503GCI
CSB-EP759503GCI
CSB-BP759503GCI
CSB-MP759503GCI
CSB-EP759503GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus UDP-N-acetylenolpyruvoylglucosamine reductase (murB) CSB-YP759504GCI
CSB-EP759504GCI
CSB-BP759504GCI
CSB-MP759504GCI
CSB-EP759504GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Bifunctional NAD (P)H-hydrate repair enzyme Nnr (nnr), partial CSB-YP759505GCI
CSB-EP759505GCI
CSB-BP759505GCI
CSB-MP759505GCI
CSB-EP759505GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Ribulose bisphosphate carboxylase large chain (cbbL) CSB-YP759506GCI
CSB-EP759506GCI
CSB-BP759506GCI
CSB-MP759506GCI
CSB-EP759506GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Sulfate/thiosulfate import ATP-binding protein CysA (cysA) CSB-YP759507GCI
CSB-EP759507GCI
CSB-BP759507GCI
CSB-MP759507GCI
CSB-EP759507GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Aspartate--tRNA ligase (aspS), partial CSB-YP759508GCI
CSB-EP759508GCI
CSB-BP759508GCI
CSB-MP759508GCI
CSB-EP759508GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Protein translocase subunit SecA (secA), partial CSB-YP759509GCI
CSB-EP759509GCI
CSB-BP759509GCI
CSB-MP759509GCI
CSB-EP759509GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Apolipoprotein N-acyltransferase (lnt), partial CSB-YP759510GCI
CSB-EP759510GCI
CSB-BP759510GCI
CSB-MP759510GCI
CSB-EP759510GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Putative pterin-4-alpha-carbinolamine dehydratase 2 (gsl1645) CSB-YP759511GCI
CSB-EP759511GCI
CSB-BP759511GCI
CSB-MP759511GCI
CSB-EP759511GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Gloeobacter violaceus Transaldolase (tal) CSB-YP759512GCI
CSB-EP759512GCI
CSB-BP759512GCI
CSB-MP759512GCI
CSB-EP759512GCI-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>